Rznomics Inc.
Research Rznomics Inc. (476830.KQ) on Bullrun: market cap KRW 620.03B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker476830.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 620.03B
- Financial periodQ2 2026
- RevenueKRW 807.82M
- Net income-KRW 6.37B
- Free cash flow-KRW 8.33B
- Gross margin100.0%
Valuation Snapshot
latest market cap is KRW 620.03B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 620.03B | n/a | n/a | n/a |
Dividend history
About Rznomics Inc.
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rznomics Inc.'s market cap?
Rznomics Inc.'s market capitalization is KRW 620.03B.
What does Rznomics Inc. do?
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.